Personalized Medicine: Are We There Yet?

- Conference provides update on progress and prospects -

Jun 23, 2010, 14:10 ET from Burrill & Company

SAN FRANCISCO, June 23 /PRNewswire/ -- With the accelerating pace of scientific discovery in life sciences, coupled with our ability to process and analyze enormous amounts of genetic information, the field of personalized medicine holds great promise for the future of healthcare.

Rapid progress is being made and the field of personalized medicine now extends beyond targeted therapeutics and diagnostics to encompass a "consumer digital health" world that includes areas such as: personal health record management, health IT, wellness and nutrition.

The 6th Annual Burrill Personalized Medicine conference, to be held in San Francisco, September 27-28, 2010 will update attendees on where we are today in the context of a turbulent, challenging economy, and a "post healthcare reform environment" and what the future holds.

The aim of the conference is to bring together stakeholders from across the value chain of personalized medicine for a fascinating set of "conversations" with experts in all these areas including: "Has "Healthcare Reform" accelerated or decelerated the move to a more Personalized Medicine world?" "The Translational Challenge: Building the Scientific Infrastructure for Personalized Medicine." "Consumer Digital Health...What's it all about?" and "What Will it Take to Get Patients to Believe in Personalized Medicine and Medicine to Deliver?"

The 6th Annual Burrill Personalized Medicine conference has become a "must attend" event providing an annual "window" into the progress of personalized medicine and the challenges and opportunities that this new paradigm presents.

Further details on the agenda may be obtained from:

About Burrill & Company

Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with activities in Venture Capital, Private Equity, Merchant Banking and Media. The Burrill family of venture capital funds has over $950 million under management and its merchant banking business is one of the industry leaders in life sciences transactions. Burrill is also the creator, sponsor and facilitator of leading industry conferences worldwide and publisher of a range of bio-intelligence reports including the monthly Burrill Report ( and annual "State of the Industry" report, the latest of which has just been released entitled Biotech 2010-Life Sciences: Adapting for Success.

SOURCE Burrill & Company